Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab and Bendamustine +/- Bortezomib in Untreated Follicular Lymphoma
NCT01286272Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 2011
- Primary completion
- May 2017
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in follicular lymphoma (FL), sponsored by National Cancer Institute. Started Apr 2011; status: completed.
02
Drugs
bortezomib
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT01286272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01286272.